



FOUNDATION OF THE
SOCIETY FOR THE STUDY OF
NEUROPROTECTION AND
NEUROPLASTICITY

INVITED SPEAKERS

Prof. dr. Ovidiu Băjenaru
Prof. dr. Dafin F. Mureșanu
Prof. dr. Natan M. Bornstein
Prof. dr. Antonio Federico

Cerebrovascular diseases | From diagnostic and treatment to neurorehabilitation

FEBRUARY 6th, 2020

RONDA Ballroom | Intercontinental Hotel | Bucharest | Romania

PROGRAM COORDINATORS



OVIDIU BĂJENARU

Corresponding Member of the Romanian Academy

Honorary President ad vitam of the Romanian Society of Neurology

Professor of Neurology and Director of the Clinical Neuroscience Department, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania

Chairman of the Department of Neurology, University Emergency Hospital Bucharest



DAFIN F. MUREȘANU

Corresponding Member of the Romanian Academy

Chair EAN Communication Committee

President of the European Federation of NeuroRehabilitation Societies (EFNR)

Past President of the Romanian Society of Neurology

Professor of Neurology, Chairman Department of Neurosciences "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania

FACULTY

IN ALPHABETICAL ORDER

Ovidiu Băjenaru / [Romania](#)

Natan M. Bornstein / [Israel](#)

Antonio Federico / [Italy](#)

Dafin F. Mureșanu / [Romania](#)

SCIENTIFIC PROGRAM



THURSDAY, 6TH OF FEBRUARY, 2020

15:50 – 16:00

WELCOME ADDRESS

16:00 – 16:45

Vasoprotection of brain microcirculation
- a key factor for reperfusion after stroke
Ovidiu Băjenaru (Romania)

16:45 - 17:30

Neurorehabilitation in stroke treatment
Dafin F. Mureșanu (Romania)

17:30 – 18:00

COFFEE BREAK

18:00 - 18:45

Post stroke cognitive impairment – current concepts and
treatment approaches
Natan M. Bornstein (Israel)

18:45 - 19:30

Genetic small vessel diseases: updates in CADASIL
and related conditions
Antonio Federico (Italy)

ABSTRACTS



VASOPROTECTION OF BRAIN MICROCIRCULATION - A KEY FACTOR FOR REPERFUSION AFTER STROKE

OVIDIU BĂJENARU^{1,2}

ANTOCHI², F Terecoasa E^{1,2}, Ribigan A^{1,2}, TIU C^{1,2}

1 University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania

2 University Emergency Hospital Bucharest – Dept. Neurology, Romania

During the last two decades, reperfusion therapy in acute ischemic stroke has significantly changed the evolution of patients with acute ischemic stroke; the most important limitations of reperfusion by fibrinolytic agents (rtPA) are the short duration of the therapeutic window for these drugs, their relative inefficiency in large arteries proximal occlusions and their potential adverse effects, mainly beyond this narrow therapeutic window.

The development of the modern endovascular thrombectomy techniques have shown major advantages and improved clinical benefits in the acute ischemic stroke. Due to clinical reasons and limited accessibility to such endovascular treatments, the present international guidelines for acute ischemic stroke recommend as first line therapy still the tPA fibrinolysis if the patients are inside the therapeutic window, which may be followed by endovascular thrombectomy if there is no significant clinical improvement at the end of the infusion with tPA, due to the longer therapeutic window and higher complexity of the procedure for thrombectomy.

The data from the scientific experimental research and clinical observations, including our clinical experience, support the idea that beyond the above mentioned reasons, there are also some delayed clinical benefits beyond immediate fibrinolysis of initial therapy with tPA, based probably on some pharmacologic and biologic properties of tPA and the individual particularities of the microvascular and collateral circulation in the brain of patients with acute ischemic stroke.

POST STROKE COGNITIVE IMPAIRMENT – CURRENT CONCEPTS AND TREATMENT APPROACHES

NATAN M. BORNSTEIN

Director of Neurological Division, Sackler school of Medicine, Tel-Aviv University, Israel

After stroke patients frequently experience a spectrum of neuropsychological and motor deficits resulting in impaired activities both cognitive and functional. About 20%-25% of patients will develop, after stroke, cognitive impairment/dementia in the months following the event.

It is still not clear who are those patients that are prone to post-stroke cognitive decline. Who are the vulnerable patients?

The aim of the Tel-Aviv Brain Acute Stroke Cohort (TABASCO) is to characterize inflammatory, stress and neuroimaging biomarkers that may predict and detect the vulnerable subjects and might outline new concepts of early interventions and novel treatment strategies for those at higher risk. The TABASCO study and its findings will be discussed.

Currently the pharmacological treatment of Post-Stroke cognitive impairment includes AchE-Is but only with modest benefit.

Cerebrolysin, a multimodal drug that mimics neurotrophic factors and maintains, protects and restores neuronal function. A COCHRANE review was conducted on the studies of Cerebrolysin, 10-30 ml/day in vascular dementia (2013), and concluded that the molecule is beneficial and safe.

Therefore, a combination of behavioral and safe and effective pharmacological adjuvant therapies will significantly improve and promote brain recovery after stroke, including cognitive impairment.

GENETIC SMALL VESSEL DISEASES: UPDATES IN CADASIL AND RELATED CONDITIONS

ANTONIO FEDERICO

Past-professor Neurology, University of Siena, Siena, Italy and professor Self-University, Zug (Switzerland)

Genetic ischemic cerebral subcortical small vessel diseases (SSVD) are rare, usually autosomal dominant conditions related to impairment of proteins mainly involved in small vessel functions. Symptoms are characterized by combinations of migraine with aura, ischemic events (transient ischemic attacks, lacunar strokes) and progressively worsening ischemic lesion load in brain imaging, vascular cognitive impairment (usually of the frontal-subcortical type) with behavioral-psychiatric symptoms and bilateral pyramidal and pseudobulbar signs leading to severe disability and premature death. In some patients, microbleeds and hemorrhagic strokes may be evident. A large clinical heterogeneity is usually present.

Between the different forms the most frequent is CADASIL, due to mutations of the NOTCH3 gene, followed by COL4A1/A2-related disease, autosomal dominant forms of HTRA1-related disease and leucoencephalopathies with calcifications and cysts. CARASIL, with an autosomal recessive HTRA1 mutation, is less frequent. A new form has been recently described, named CARASAL.

Here we will report our experience with these patients describing recent data on their pathogenesis and some guideline on the diagnosis and therapeutic options.

NEUROREHABILITATION IN STROKE TREATMENT

DAFIN F. MUREȘANU

Chairman Department of Neurosciences

University of Medicine and Pharmacy 'Iuliu Hatieganu', Cluj-Napoca, Romania

Over the last decades, therapeutic approaches for stroke have significantly evolved and improved as a consequence of the implementation of modern stroke units, improvement of general medical care and more structured and early administered rehabilitation schemes.

Thrombolytic therapy with rt-PA (recombinant tissue plasminogen activator) has been developed and a number of clinical trials have recently confirmed the effectiveness of thrombectomy to be better than rtPA alone.

Except thrombolytic therapy and thrombectomy there is still no widely accepted therapy for acute ischemic stroke. Current data shows that even if advanced procedures can be used, 60% of stroke patients die or remain with a certain level of deficit. As it is widely accepted that immobilization-related complications cause over 50% of stroke patients' deaths, rehabilitation plays an important role in stroke care.

It is getting clearer that multimodal drugs may play an important role in pharmacological support of neurorehabilitation after stroke.

The results of recently published large and well-controlled clinical studies show a positive effect of Cerebrolysin on neurological recovery after acute ischemic stroke. The newly published CARS study assessed the efficacy and safety of Cerebrolysin in combination with a standardized rehabilitation program. The primary study endpoint was the Action Research Arm Test (ARAT) at day 90, assessing upper-limb motor functions. Cerebrolysin was administered for 21 days, starting within 48-72 hours after ischemic stroke.

The study showed a statistically significant group difference in the upper-limb motor function (ARAT) at day 90 – primary end point. Cerebrolysin was also superior over placebo in most of the secondary endpoints like the NIHSS, Barthel Index and mRS. Also, at day 90, patients treated with Cerebrolysin showed less depressive symptoms and better quality of life. In addition, the most important measure for early benefit, the NIHSS at day 21, showed statistically significant superiority of Cerebrolysin. Analysis of the safety parameters did not show any clinically statistical significant differences between the treatment groups. The trial

indicates that early combination of rehabilitation with a multimodal medication of neuroprotective and recovery properties is a valid therapeutic approach.

Furthermore, CARS 1 and CARS 2 meta-analysis provides evidence that Cerebrolysin has a beneficial effect on motor function recovery in early rehabilitation patients after stroke. All pre-planned primary meta-analytic results were statistically significant.

CURRICULUM VITAE





OVIDIU BĂJENARU

ROMANIA

Corresponding Member of the Romanian Academy

Member of the Romanian Academy of Medical Sciences

Professor of Neurology and Director of the Clinical Neuroscience Department at the University of Medicine and Pharmacy "Carol Davila" Bucharest,

Chairman of the Department of Neurology, University Emergency Hospital Bucharest

- Graduate of the Faculty of Medicine – University of Medicine and Pharmacy (UMF) „Carol Davila” Bucharest (1983)
- Specialist in Neurology (1989), Senior Neurologist (1994); competence in MRI diagnostic in neurologic disorders (1991)
- PhD (1993) - UMF „Carol Davila” Bucharest
- 2006: Doctor Honoris Causa –University „Ovidius” – Constanta
- Postdoctoral specialization at the University „René Descartes” (Paris) during 1993-1994, in clinical Neurology (CHU „Saint-Anne” and „Kremlin-Bicetre”) and research grants in Clinical and Experimental Neurophysiology (CHU „Cochin-Port Royale”and Faculté de Medecine Paris V)
- 2001-2013: President of the Romanian Society of Neurology
- Since 2013: Honorary President ad vitam of the Romanian Society of Neurology
- Since 2001: Coordinator and Chairman of all annual National Congresses of the Romanian Society of Neurology and many other scientific events and teaching courses organized for neurologists in Romania
- Visiting Professor in Vietnam (2013) and Kazakhstan (2015) on behalf of WFN
- Member of the Executive Committee of ENS (European Society of Neurology) between 2005-2009, of the Scientific Committee of ECTRIMS (2004-2009)



NATAN M. BORNSTEIN

ISRAEL

EDUCATION

1970-73 University of Sienna, Medicine, Sienna, Italy
1973-79 Technion Medical School, Hifa, Medicine, MD, 1979
Date of receiving specialixation certificate: 11 September, 1984
Title of Doctoral dissertation: Dextran 40 in acute ischemic stroke
Name of Supervisor: Dr. Jacob Vardi

FURTHER EDUCATION

1978-83 Tel-Aviv University, Sackler Faculty of Medicine, neurology
(residence), Israeli Board certified in Neurology, 1983
1979-83 Tel-Aviv University, Sackler Faculty of Medicine, Post graduate
studies in Neurology
1984-87 Sunnybrook Medical Center, University of Toronto, M.R.C stroke,
Fellowship

ACADEMIC AND PROFESSIONAL EXPERIENCE

1982-1995 Tel-Aviv University, Neurology, instructor
1991-present European stroke Conference (ESC), Executive committee
1995-1999 Tel-Aviv University, Neurology, Senior lecturer
1995 Eliprodil CVD 715 clinical trial, Steering Committee
1995-1997 International Stroke Study (IST), Steering Committee
1995-1999 American Academy of Neurology, Member of the International
Affairs Committee
1996 Asymptomatic Carotid Stenosis and Risk of Stroke(ACSRS), Advisory
Committee
1996-present The Mediterranean Stroke Society (MSS), President
1996-2002 EFNS, Management Committee
1997-2009 Israeli Neurological Association, Secretary
1999-present Tel-Aviv University, Neurology, Associated Professor
2001- present European Society Neurosonology and Cerebral Hemodynamics
(ESNCH) Executive committee
2005-present Neurosonolgy Research Group, Executive committee
2006-present European Master in Stroke Medicine, Member of faculty

2006-2008	NEST II clinical Trial, Steering Committee
2006-present	SENTIS clinical Trial, Steering Committee
2006-present	CASTA Trial, Steering Committee
2006-present	Brainsgate clinical Trial, Steering Committee
2008- present	World Stroke Association (WSO), Vice president
2009-present	Israeli Neurological Association, Chairman
2009-present	European Stroke Organization (ESO), Member on the board of directors
2010-	NEST III clinical Trial, Steering Committee

PROFESSIONAL ACHIEVEMENTS- EDITORIAL BOARD

1991-present	Neurological Research Journal, Guest Editor
1991-present	STROKE, Member of the editorial board
1998-present	European Journal of Neurology, Member of the editorial board
1999-present	Journal of Cerebrovascular disease, Member of the editorial board
2000-present	Journal of Annals of Medical Science, Consulting Editor
2001-present	Journal of Neurological Science (Turkish), Member of the editorial board
2001-present	Acta Clinica Croatica, Member of the editorial Council
2003-present	Italian Heart Journal, International Scientific Board
2003-present	Journal of Neurological Sciences, Guest Editor
2004-present	Turkish Journal of Neurology, International Advisory Board
2005-present	Archives of Medical Sciences (AMS) , Member of the Editorial Board
2006-present	Journal of Cardiovascular Medicine, International Scientific Board
2006-present	International Journal of Stroke, Editorial Board
2006-present	Acta Neurologica Scandinavica, Editorial Board
2009-present	American Journal of Neuroprotection& Neurogeneration (AJNN) Member of the Editorial Board
2010	Neurosonology, International Editorial Board
2010	Frontiers in Stroke, Review Editor

PROFESSIONAL ACHIEVEMENTS- REVIEWER

1998-present	Lancet, Ad Hoc reviewer
1998-present	Diabetes and its complications, Ad Hoc reviewer
1999-present	Journal of Neuroimaging, Reviewer
1999-present	Journal of Neurology, Ad Hoc reviewer
2000-present	Neurology, Ad Hoc reviewer
2003-present	Israeli Medical Association Journal (IMAJ), Reviewer
2003-present	Acta Neurologica Scandinavica, Ad Hoc reviewer
2006-present	Journal of Neurology, Neurosurgery & Psychiatry, Reviewer
2010-	European Neurology, Ad Hoc reviewer

MEMBERSHIP IN PROFESSIONAL SOCIETIES

1977-present	Israeli Medical Association
1983-present	The Israeli Neurological Association
1985-present	Stroke Council of the American Heart Association (Fellow)
1986-present	American Academy of Neurology

1986-present	Neurosonology Research Group of the World Federation of Neurology
1987-present	Stroke Research Group of the World Federation of Neurology
1990-2008	International Stroke Society
1995-2008	European Stroke Council
1995-present	Mediterranean Stroke Society (MSS)
1998-present	European Neurosonology Society
2005-present	World Stroke Organization (WSO)
2008-present	Fellow of the European Stroke organization (FESO)



ANTONIO FEDERICO

ITALY

Prof. Antonio Federico, born in Polla (Sa) on the 25.08.48, from 1990 is full professor of Neurology at the University of Siena , Director of the Unit Clinical Neurology and Neurometabolic Disease.

He was Director of the Department of Neurological, Neurosurgical and Behavioural Sciences, University of Siena (2002-2008).

He received the degree in Medicine and specialization in Nervous and Mental Diseases, summa cum laude, at the University of Naples in 1972 and 1975 respectively. He received the Lepetit Award for the best degree dissertation in 1972.

His biological training was in the Institute of Biochemistry as student and after in Physiology of the University of Naples, and in the Centre de Neurochimie of CNRS, in Strasbourg, directed by prof. Mandel where he worked in the years 1973-75. He also collaborated with many international research groups, in different countries where he spent in the past years some times: in Montreal (Prof. Andermann, Karpati and Shoudgbridge), in London (dr A. Harding and prof. Morgan-Hughes), in Toronto (dr.Robinson), in Bonn (prof. von Bergmann), in Paris (dr.Baumann), in Baltimore (proff. Moser and Naidu), in Oxford (prof. Matthews), etc. His clinical formation was made at the Medical School of the University of Naples, in the Dept, Neurology, and after in Siena, where he moved on 1980 with his mentor, prof. G.C. Guazzi. Associated professor in Neurology in 1982, since 1990 he is full professor of Neurology, Medical School, University of Siena. In 2013, he received honoris causa degree in Medicine at University Carol Davila, Bucharest, Rumania.

In the years 1990-96 he was Secretary of the Italian Society of Neurology. In the years 2006-08 was President of the Italian Society of Neurology. He coordinated the Study Group on Clinical Neurogenetics of the Italian Society of Neurology. He has been referee for projects evaluation in the area of Orphan drugs and Orphan diseases for Biomed Projects from EU, for MURST, CNR and Istituto Superiore di Sanita, and other national and international funding agencies, etc.

He is member of the Second Opinion Group of the American Leucodystrophy Association. Associated editor of Neurological Sciences , Springer-Verlag Editor from 2000. From 2012, he is Editor-in Chief.

He is author of more than 500 article quoted by Pubmed. He is author of a chapter on Cerebrotendinous Xanthomatosis, Vinken and Bruyn Edts, Handbook of Clinical Neurology, vol 49, Neurodystrophies and Neurolipidoses.

On the book McKusick's Mendelian Inheritance in Man., Ed.1992, Catalog of Autosomal Dominant and Recessive Phenotypes he is cited for 3 different diseases. He was editor of the book Late Onset Neurometabolic diseases (A.Federico, K. Suzuki and N.Baumann Edts), Karger 1991, and many other books from Italian and international.

Publishing Companies. Recently he published (2015) Manuale di Neurologia Pratica and Neurologia and Assistenza infermieristica, for students.

His main field of interest is related to neurometabolic, neurodegenerative and rare diseases, investigated from a genetic, metabolic, neuroimaging and clinical point of view. Summary of the academic involvements: - Director of the Section Neurological Sciences, Dept Neurological , Neurosurgical and Behavioural Sciences (2000-2012) - Director of the Research Center for the Diagnosis, Therapy and Prevention of the Neurohandicap and Rare Neurological Diseases, until the 2010 - Vice-Dine of the Medical School, University of Siena (2003- 2006) - Director of the Postgraduate School of Neurology, University of Siena, from 2006 up to 2014. - Director of the PhD School in Cognitive and Neurological Sciences, University of Siena (from 2000 up to date) - Coordinator of the Section of the Univ. Siena of the PhD Program Neurosciences, Univ. Florence. - Research delegate for the Dept Medicine, Surgery and Neurosciences (2013-2018) - Vice-Rector of the University of Siena, from 1st april 2016 to november 2017.

Medical Involvements – Until November 2018 (date of retirement) Director of the OU Clinical Neurology and Neurometabolic Diseases, University Hospital of Siena Medical School. –He is still Director of the Regional Reference Center for Rare Diseases - Regional Coordinator of the Network for Rare Neurological Diseases, Tuscany Region. - Member of several Ministry of Health and Regional Committees National and International Commitments - President of the Italian Society of Neurology (2009-11) - Italian delegate to the World Federation of Neurology - Italian Delegate to the European Union of Medical Specialists (Section Neurology) - Italian Delegate and Chairman of the Neuromediterraneum Forum and President - Consultive

Member of the European Brain Council - Editor - in - Chief of Neurological Sciences, Springer Verlag Editor. He is in the Editorial Board of many national and international journals. - Member of the American Panel United Leucodystrophies. - Member of the Scientific Committee of AISM (Associazione Italiana Sclerosi Multipla) - Chairman of the Scientific Committee of the European Academy of Neurology (2014-2018) - Chairman of Neuromediterraneum Forum - Co-Chairman of Research group of WFN Migration Neurology. Member of the Scientific Societies: - Societa Italiana di Neurologia (Past Secretary, President, Past-President and Member of the Committee) - Society for the Inborn Errors of Metabolism - Italian Association of Neuropathology - SINDEM (Italian Association of Dementias) - Italian Association for Parkinson's disease - Italian Association of Neurogeriatrics (Member of the Scientific Committee) - Italian Stroke Forum - European Academy of Neurology (Member of the Board and Chairman of the Scientific Committee) - American Academy of Neurology - World Federation of Neurology (Co-Chair Section of Migration Neurology) - Neuromediterraneum Forum (President).



DAFIN F. MUREȘANU
ROMANIA

Professor of Neurology, Senior Neurologist, Chairman of the Neurosciences Department, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, President of the European Federation of Neurorehabilitation Societies (EFNR), Chair EAN Communication Committee, Co-Chair of the EAN Neurotraumatology Scientific Panel, Past President of the Romanian Society of Neurology, President of the Society for the Study of Neuroprotection and Neuroplasticity (SSNN), Member of the Romanian Academy, Member of the Academy of Medical Sciences, Romania, secretary of its Cluj Branch. He is member of 17 scientific international societies (being Member of the American Neurological Association (ANA) - Fellow of ANA (FANA) since 2012) and 10 national ones, being part of the executive board of most of these societies.

Professor Dafin F. Muresanu is a specialist in Leadership and Management of Research and Health Care Systems (specialization in Management and Leadership, Arthur Anderson Institute, Illinois, USA, 1998 and several international courses and training stages in

Neurology, research, management and leadership). Professor Dafin F. Muresanu is coordinator in international educational programs of European Master (i.e. European Master in Stroke Medicine, University of Krems), organizer and co-organizer of many educational projects: European and international schools and courses (International School of Neurology, European Stroke Organisation summer School, Danubian Neurological Society Teaching Courses, Seminars - Department of Neurosciences, European Teaching Courses on Neurorehabilitation) and scientific events: congresses, conferences, symposia (International Congresses of the Society for the Study of Neuroprotection and Neuroplasticity (SSNN), International Association of Neurorestoratology (IANR) & Global College for Neuroprotection and Neuroregeneration (GCNN) Conferences, Vascular Dementia Congresses (VaD), World Congresses on Controversies in Neurology (CONy), Danube Society Neurology Congresses, World Academy for Multidisciplinary Neurotraumatology (AMN) Congresses, Congresses of European Society for Clinical Neuropharmacology, European Congresses of Neurorehabilitation). His activity includes involvement in many national and international clinical studies and research projects, over 400 scientific participations as "invited speaker" in national and international scientific events, a significant portfolio of scientific articles (209 papers indexed on Web of Science-ISI, H-index: 22) as well as contributions in monographs and books published by prestigious international publishing houses.

Prof. Dr. Dafin F. Muresanu has been honoured with: „Dimitrie Cantemir” Medal of the Academy of The Republic of Moldova in 2018, Ana Aslan Award 2018 - "Performance in the study of active aging and neuroscience", for the contribution to the development of Romanian medicine, National Order "Faithful Service" awarded by the President of Romania in 2017; "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Faculty of Medicine, the "Iuliu Hatieganu Great Award 2016" for the best educational project in the last five years; the Academy of Romanian Scientists, "Carol Davila Award for Medical Sciences / 2011", for the contribution to the Neurosurgery book "Tratat de Neurochirurgie" (vol.2), Editura Medicala, Bucuresti, 2011; the Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca "Octavian Fodor Award" for the best scientific activity of the year 2010 and the 2009 Romanian Academy "Gheorghe Marinescu Award" for advanced contributions in Neuroprotection and Neuroplasticity.



“RoNeuro”

Institute for Neurological Research and Diagnostic,
Cluj-Napoca, Romania

Tel.: 0374 46.22.22

str. Mircea Eliade nr. 37, 400364 Cluj-Napoca, România
Fax: 0374.461.674; Email: receptie@roneuro.ro

www.roneuro.ro